Faecal Microbiome Transplantation as a Solution to Chronic Enteropathies in Dogs: A Case Study of Beneficial Microbial Evolution

• Published in: Animals (Basel) 2021-05, Vol.11 (5), p.1433
• Main Authors: Berlanda, Michele, Innocente, Giada, Simionati, Barbara, Di Camillo, Barbara, Facchin, Sonia, Giron, Maria, Savarino, Edoardo, Sebastiani, Federico, Fiorio, Francesca, Patuzzi, Ilaria
• Format: Article
• Language: English
• Subjects: Abdomen; Animal diseases; Antibiotics; Biochemistry; Blood tests; Body weight; Case Report; chronic diseases; Colonoscopy; Diarrhea; Digestive system; Disease; Diversity indices; Dogs; Domestic animals; Drug therapy; Endoscopy; enteropathy; Evolution; faecal microbiome transplantation; FMT; Gastrointestinal diseases; Health services; Immune system; Intestinal microflora; Intestine; Medical treatment; Metabolism; microbiome; Microbiomes; Microbiota; Microorganisms; Next-generation sequencing; Nutrients; Patients; Pets; Probiotics; Quality of life; rRNA 16S; Signs and symptoms; Syntrophism; Taxonomy; Transplantation; Ultrasonic imaging; Vomiting
• ISSN: 2076-2615; 2076-2615
• DOI: 10.3390/ani11051433

Chronic enteropathies (CE) are gastrointestinal diseases that afflict about one in five dogs in Europe. Conventional therapeutic approaches include dietary intervention, pharmacological treatment and probiotic supplements. The patient response can be highly variable and the interventions are often not resolutive. Moreover, the therapeutic strategy is usually planned (and gradually corrected) based on the patient’s response to empirical treatment, with few indirect gut health indicators useful to drive clinicians’ decisions. The ever-diminishing cost of high-throughput sequencing (HTS) allows clinicians to directly follow and characterise the evolution of the whole gut microbial community in order to highlight possible weaknesses. In this framework, faecal microbiome transplantation (FMT) is emerging as a feasible solution to CE, based on the implant of a balanced, eubiotic microbial community from a healthy donor to a dysbiotic patient. In this study, we report the promising results of FMT carried out in a 9-year-old dog suffering from CE for the last 3 years. The patient underwent a two-cycle oral treatment of FMT and the microbiota evolution was monitored by 16S rRNA gene sequencing both prior to FMT and after the two administrations. We evaluated the variation of microbial composition by calculating three different alpha diversity indices and compared the patient and donor data to a healthy control population of 94 dogs. After FMT, the patient’s microbiome and clinical parameters gradually shifted to values similar to those observed in healthy dogs. Symptoms disappeared during a follow-up period of six months after the second FMT. We believe that this study opens the door for potential applications of FMT in clinical veterinary practice and highlights the need to improve our knowledge on this relevant topic.